Alpha Teknova Stock Earnings Reports

Alpha Teknova delivered a solid start to 2026 with revenue up 13% year-over-year to just over $11 million for Q1, driven by an 85% increase in Clinical Solutions (GMP products) while Lab Essentials (RUO catalog/custom) was largely stable (+3%). Gross margin improved to 34.2% and adjusted EBITDA narrowed to negative $2.0 million. Operating expenses were $8.1 million, reflecting a planned ~$2 million annual increase in commercial spend (sales and marketing) to be fully deployed in 2026. Net loss was $4.6 million (‑$0.08 per share). Cash, cash equivalents, and short-term investments were $17.8 million with $13.2 million of borrowings. Management reiterated 2026 revenue guidance of $42–$44 million (midpoint ≈ 6% growth) and expects full‑year free cash outflow < $10 million. Key strategic initiatives include expanding commercial teams (ramp 6–12 months), production scaling (tripled single-batch bottle size, new automated aseptic filling), and digitization (90 of ~3,000 paper batch records migrated). Management emphasized market stabilization, improving customer ordering (more >$25k orders), and a path to higher growth: targeting ~20% revenue growth in 2027 and adjusted EBITDA breakeven as revenue reaches $52–$57 million. Risks highlighted include quarter-to-quarter lumpiness in Clinical Solutions, macro/biotech funding uncertainty, and the time needed for commercial investments to materialize.